Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowHROW -1.05%81 PB Ratio is 53.69 as of Jul. 15, 2026, which is 285% above its 10-year median of 13.94. GuruFocus rates HROW with a GF Score™ of 81/100 and a GF Value™ of $43.13 (Fairly Valued). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Harrow ranks worse than 99.13% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Harrow's share price is $41.34. Harrow's Book Value per Share for the quarter that ended in Mar. 2026 was $0.77. Hence, Harrow's PB Ratio of today is 53.69.
Warning Sign:
Harrow Inc stock PB Ratio (=54.3) is close to 3-year high of 55.68.
The historical rank and industry rank for Harrow's PB Ratio or its related term are showing as below:
HROW'
s PB Ratio Range Over the Past 10 Years
Min: 2.92 Med: 13.94 Max: 612.5
Current: 53.73
During the past 13 years, Harrow's highest PB Ratio was 612.50. The lowest was 2.92. And the median was 13.94.
HROW's PB Ratio is ranked worse than 99.13% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs HROW: 53.73
During the past 12 months, Harrow's average Book Value Per Share Growth Rate was -51.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 15.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Harrow was 154.10% per year. The lowest was -47.50% per year. And the median was 15.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Harrow PB Ratio Related Terms
Harrow PB Ratio Historical Data
* Premium members only.
The historical data trend for Harrow's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's PB Ratio distribution charts can be found below:
* The bar in red indicates where Harrow's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Harrow's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Harrow (HROW) has a PB Ratio of 53.69 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Harrow and its competitors. This is 285% above median its historical median of 13.94. Over the past decade, Harrow's PB Ratio has ranged from 2.92 to 612.50. According to the industry distribution chart, Harrow ranks #913 out of 921 companies in the Drug Manufacturers industry, placing it in the top 99.1%.
Is Harrow's PB Ratio too high?
Harrow's current PB Ratio of 53.69 is 285% above median its 10-year median of 13.94. Over the past 10 years, this metric has ranged from a low of 2.92 to a high of 612.50. The Drug Manufacturers industry median PB Ratio is 1.90. Harrow's value of 53.69 is 2725.8% above this industry median. Based on the distribution chart, Harrow ranks #913 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Harrow has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's PB Ratio compare to TRLV and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #913 out of 921 companies for PB Ratio. This places Harrow in the lower half of its industry. The industry median PB Ratio is 1.90. Harrow's value of 53.69 is 2725.8% above this benchmark. Historically, Harrow's own PB Ratio has ranged from 2.92 to 612.50 over the past decade. While the company's 10-year median is 13.94 vs. the industry median of 1.90, Harrow has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harrow's current PB Ratio of 53.69 is 2725.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Harrow and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current PB Ratio is 53.69, which is 285% above median its own 10-year median of 13.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $43.13, compared to a current price of $41.34 — trading 4.2% below its estimated fair value. The current PB Ratio is 53.69, which is 285% above median its 10-year median of 13.94 and 2725.8% above the Drug Manufacturers industry median of 1.90. Harrow's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Harrow (HROW), the current PB Ratio is 53.69 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (HROW) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of $41.34 is trading 4.2% below its estimated GF Value™ of $43.13.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for HROW:
PB Ratio: 53.69 (285% above median its 10-year median of 13.94)
GF Value™: $43.13 vs. price of $41.34 (4.2% below fair value)
Industry Position: 2725.8% above the Drug Manufacturers median (#913 of 921)
No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
81GF Score
Get the complete analysis for HROW
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HROW has been successfully added to your 
